How PE Firms Use Expert Networks to Diligence Healthcare and Telehealth Platform Deals

Healthcare and telehealth are back at the top of the PE deal pipeline — and the traditional due diligence playbook is breaking under the weight of regulatory cliff risk, reimbursement complexity, and clinical workflow nuance that no data room can answer. Healthcare PE deal value rose 45% year-over-year in 2025, and in Q1 alone the sector saw 77 transactions involving patient engagement, telehealth, and medical practice management technologies. At the same time, fee-for-service telemedicine visits dropped 24% the month Medicare's telehealth flexibilities lapsed in September 2025, and the DEA's Fourth Temporary Extension only buys the industry until December 31, 2026.

If you're underwriting a telehealth, behavioral health, or HCIT platform in 2026, you cannot answer the questions that matter — Will payers keep reimbursing this? Are clinicians actually using the platform? Does this MSO/PC structure hold up? — from a CIM and a QofE alone. You need primary research. And the way most PE deal teams use expert networks for healthcare deals is sub-optimal.

This guide is a practitioner's playbook for running primary research on a healthcare or telehealth deal: who to talk to, what to ask, how to structure the workstream against your financial model, and where volume expert networks consistently fall short.

Why healthcare and telehealth DD is breaking traditional PE playbooks

Three forces are converging on every healthcare deal underwritten right now:

1. Regulatory cliff risk. The DEA/HHS Fourth Temporary Extension keeps COVID-era controlled-substance telemedicine flexibilities alive through December 31, 2026. After that, the proposed Special Registration framework — including a per-state $888 registration, mandatory PDMP checks, and tighter recordkeeping — could compress prescribing volume overnight for any DTC platform touching controlled substances (ADHD, OUD, pain, ketamine, even GLP-1 adjacencies).
2. Reimbursement re-pricing. CMS issued the CY2026 Medicare Physician Fee Schedule Final Rule on October 31, 2025, with revisions to supervision requirements and telehealth payment policies effective January 1, 2026. Combined with the September 2025 lapse of Medicare telehealth flexibilities that drove a 24% drop in fee-for-service telemedicine visits, the reimbursement floor under most telehealth models has moved — and your model needs to reflect it.
3. State-level scrutiny of PE. Massachusetts, Oregon, California, and others are tightening reporting and pre-approval requirements for PE-backed healthcare deals. CPOM (Corporate Practice of Medicine) structures and friendly-PC arrangements are getting more attention from state AGs, not less.

None of this lives in the data room. All of it can be unpacked, in days, through structured calls with practicing clinicians, payer medical directors, RCM leads, and former state regulators — if you know how to recruit them and what to ask.

The misconception that costs PE firms money: "former executives are enough"

The single most expensive habit in healthcare DD is staffing your expert calls almost entirely with former C-suite executives from the target or its competitors. Three problems:

• They're optimistic by construction. They built or sold the businesses you're now diligencing. Their priors line up with management's narrative.
• They're dated. A former Teladoc VP who left in 2022 has no view on 2026 prescribing behaviour under the Fourth Extension.
• They're recycled. Volume networks (GLG, AlphaSights, Third Bridge, Guidepoint) maintain large rosters but the same 15 names appear on every healthcare deal in the sector. Convergent views are not the same as correct views.

The people who hold the truth on a healthcare deal are the people who currently use or reject the platform: practicing nurse practitioners, supervising MDs, billing managers, payer contracting officers, and clinic admins. They will tell you which CPT codes get denied, which workflows clinicians abandon after week three, and whether the "1,800 active providers" in the management deck are W-2 retained clinicians or 1099 churn.

The five expert archetypes you need on every healthcare deal

Map your expert list to the healthcare value chain before you write a single discussion guide.

1. Practicing clinicians (MD, DO, NP, PA, RN, LCSW, BCBA). Currently prescribing, scheduling, or delivering care through the platform — or a direct competitor. They answer: Does the workflow actually work? Would you switch? What breaks?
2. Practice managers and clinic administrators. Owners of operational reality. They answer: Clinician retention truth, scheduling utilisation, onboarding friction, and the gap between contracted and active providers.
3. Revenue cycle / billing managers. The single most underused archetype in PE healthcare DD. They answer: Denial rates by CPT code, days in A/R, payer-mix truth, and which lines of revenue are most likely to be down-coded or audited.
4. Payer-side experts (medical directors, network managers, contract managers). The highest-ROI hour in any telehealth diligence. They answer: Will this contract renew? At what rate? What's the reimbursement durability through 2027?
5. State regulators and former Medicaid/CMS/DEA officials. They answer: Will the DEA Special Registration final rule favor your target's model? Is the CPOM structure aggressive relative to peers? Which state attorneys general are watching the category?

For DTC telehealth specifically, add a sixth: patient/member panels. Anonymous N=200+ surveys of current and lapsed users are the only credible way to validate CAC, LTV, and substitution risk in a DTC mental health, GLP-1, or men's-health platform.

A framework: mapping expert calls to your financial model

Expert calls that don't change a model assumption or a thesis element are wasted. Before you commission a single call, write down your top five thesis assumptions and force each one to map to a research workstream.

After every call, update the base, upside, and downside scenarios. If a call doesn't move a number or kill an assumption, your discussion guide was wrong.

The 10 questions that consistently break or confirm a telehealth thesis

Drop these into your discussion guide as starting points. They're designed to elicit specifics, not narrative.

1. "Walk me through the last time you prescribed via [platform]. What broke? What didn't?"
2. "Of the clinicians you onboarded in the last 12 months, how many are still actively seeing patients on the platform monthly?"
3. "Which CPT codes is the platform billing most heavily, and which do you expect to be down-coded in the next 18 months?"
4. "What percentage of your visit volume depends on the DEA telemedicine flexibilities, and what's your contingency if the Special Registration final rule adds friction?"
5. "How does the platform's reimbursement compare to in-person equivalent CPT codes from your top three payers?"
6. "If you were a health system CMIO, would you build this in-house with Epic + a contracted clinician network, or buy from [target]? At what price point does that change?"
7. "In your state, how aggressive is the friendly-PC / MSO structure relative to peers — and which AG offices are paying attention?"
8. "What's the realistic churn rate of 1099 clinicians on platforms like this in the first 12 months?"
9. "For DTC categories: what share of your patients would switch to a competitor for a 10% lower monthly subscription?"
10. "What is the platform most likely to be wrong about in their pitch?"

Reimbursement and regulatory DD: what to ask, and whom

Reimbursement risk is not a legal DD issue to be addressed in a week-5 memo. It's the revenue model. Run a regulatory track in parallel with your commercial track from day three.

For DEA / controlled substances exposure: Call former DEA Diversion Control officials and current pharmacy benefit managers. Ask specifically about the diversion enforcement posture, the Special Registration $888 per-state cost layered across the target's prescribing footprint, and the multi-state PDMP requirement.

For Medicare/Medicaid exposure: Call former CMS officials and state Medicaid medical directors. Ask about CY2026 PFS impact on the target's top revenue codes, supervision requirement changes, and whether state Medicaid telehealth parity is durable.

For CPOM and MSO structure: Call healthcare regulatory attorneys with state-board experience (not federal-only experts — this is where volume networks fail). Ask about the friendly-PC ownership chain, management fee structures, and recent enforcement actions in target-state operating jurisdictions.

Why volume expert networks underperform on healthcare deals

GLG, AlphaSights, Third Bridge, and Guidepoint are excellent for breadth and speed in generalist sectors. On healthcare deals they have three structural limitations:

• Roster recycling. The same former executives appear across every deal in the category. By the time the third PE bidder calls them, their views are well-rehearsed and well-aligned with the sell-side narrative.
• Per-call meter. The pricing model rewards call volume, not synthesis. You end up with 15 transcripts and no thesis update.
• Generalist recruiters. Finding a billing manager at a 30-clinician dermatology PPM in Texas in 48 hours is a different recruiting problem from finding a former Fortune 500 CFO. Volume networks are built for the latter.

The alternatives are custom-recruit providers and done-for-you primary research firms that recruit practicing operators against a deal-specific brief, run the calls, run a complementary B2B survey, and deliver a finished thesis update rather than transcripts. That's where Woozle Research sits.

Combine expert calls with a B2B survey for statistical confidence

A dozen expert calls give you depth. They cannot give you confidence intervals on NPS, willingness-to-renew, or competitive substitution. For any healthcare or telehealth deal where clinician retention, patient retention, or customer satisfaction is a top-three thesis assumption, run a 200–400 respondent survey alongside the calls.

Anonymous surveys catch what no clinician will say on a recorded call: that they're already evaluating a competing platform, that they only stay because their employer mandates it, or that the workflow is materially worse than the prior tool. Run the survey in week 1, use the quant signal to sharpen discussion guides for weeks 2–3, and triangulate.

A 4-week sample timeline for healthcare DD primary research

• Week 1. Brief in. Map thesis assumptions to workstreams. Launch B2B survey. Recruit and complete 4–6 calls with practicing clinicians and practice admins.
• Week 2. 6–8 calls across payer contacts, RCM leads, and competitive intel. First model variance log delivered.
• Week 3. 4–6 calls on regulatory track (DEA, CMS, state CPOM). Survey closes; cross-tab analysis delivered. Red-flag register updated.
• Week 4. Confirmatory calls on residual unknowns. Final thesis memo with model sensitivities (e.g., DEA Special Registration final rule passing favorably vs. delayed; CY2026 PFS impact on top three CPT codes).

Total: 12–25 expert touchpoints across 5–7 stakeholder groups, plus a 200–400 respondent survey, mapped to IC-memo-ready deliverables.

What "good" looks like at IC

• Three independent triangulations on each of the top five thesis assumptions
• Reimbursement-scenario sensitivities tied to specific regulatory pathways
• A red-flag register that drove at least one model adjustment per workstream
• A documented MNPI screening and compliance trail for every expert touchpoint
• The same expert network reusable for the 100-day plan, payer contracting, and add-on sourcing post-close

How Woozle approaches healthcare primary research

Woozle is a done-for-you primary research provider for PE deal teams. On a healthcare or telehealth deal, we:

• Recruit currently practicing clinicians, admins, RCM leads, and payer contacts — not retired executives from a static database
• Run the expert calls and B2B surveys end-to-end so your team isn't writing discussion guides or synthesising transcripts at 11pm
• Mix calls, surveys, and channel checks in a single workstream priced to the deal calendar, not per call
• Deliver thesis updates, model variance logs, and red-flag registers — not transcripts
• Stay engaged post-close for the 100-day plan, payer contracting work, and add-on sourcing

If you're running diligence on a telehealth, behavioral health, HCIT, or physician-services platform and you want practicing-clinician access, payer-side calls, and a survey-backed read inside a four-to-six week window, get in touch with our team. We'll scope the workstream against your thesis and your IC date.